Cellebrite DI (NASDAQ:CLBT – Get Free Report) issued its quarterly earnings results on Thursday. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03), Zacks reports. Cellebrite DI had a positive return on equity of 122.59% and a negative net margin of 82.28%. Cellebrite DI updated its FY 2025 guidance to EPS and its Q1 2025 guidance to EPS.
Cellebrite DI Stock Down 5.5 %
Shares of NASDAQ CLBT opened at $20.50 on Friday. Cellebrite DI has a 12-month low of $9.96 and a 12-month high of $26.30. The firm’s 50-day moving average is $22.58 and its two-hundred day moving average is $19.10.
Wall Street Analysts Forecast Growth
A number of research analysts have recently issued reports on the stock. Craig Hallum boosted their price target on shares of Cellebrite DI from $23.00 to $24.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Lake Street Capital boosted their price target on shares of Cellebrite DI from $17.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday. JPMorgan Chase & Co. boosted their price target on shares of Cellebrite DI from $24.00 to $28.00 and gave the stock an “overweight” rating in a research note on Tuesday. Finally, Needham & Company LLC restated a “buy” rating and set a $28.00 target price on shares of Cellebrite DI in a research report on Friday. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, Cellebrite DI has a consensus rating of “Buy” and an average price target of $23.43.
About Cellebrite DI
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
See Also
- Five stocks we like better than Cellebrite DI
- What is a buyback in stocks? A comprehensive guide for investors
- Roblox’s Big Dip: A Chance to Get in on the Vaunted Gaming Stock?
- What is Put Option Volume?
- 3 Dividend ETFs to Capitalize on the Slide in Chip Stocks
- What is the S&P 500 and How It is Distinct from Other Indexes
- Is Chevron Stock Primed for Growth After Profit-Boosting News?
Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.
